EraGen Biosciences

About EraGen Biosciences

EraGen Biosciences, founded in 1999, operated in the molecular diagnostics sector, focusing on the development and manufacturing of molecular reagent products for clinical laboratories and medical researchers. The company's core business involved creating DNA and RNA-based tests for the early detection and monitoring of infectious diseases and genetic conditions. In June 2011, Luminex Corporation acquired EraGen for approximately $34 million in cash, incorporating EraGen's technology and product portfolio to expand its own molecular diagnostics capabilities.

Dr. Irene Hrusovsky, a board-certified pediatrician with extensive experience in medical devices, diagnostics, and pharmaceuticals, served as the President and CEO of EraGen. She joined the company in 2002 and was instrumental in transitioning it from a research-focused lab into a fully commercial operation, which culminated in its successful acquisition. Before EraGen, Dr. Hrusovsky held executive positions at Abbott Laboratories and served as Vice President at GlaxoSmithKline, bringing a wealth of industry experience that guided EraGen's growth.

The company's key offering was its patented MultiCode® platform chemistry, a flexible technology for both real-time and multiplex polymerase chain reaction (PCR) applications. This platform formed the basis of its diagnostic assays. A notable product was the MultiCode-RTx Herpes Simplex Virus (HSV) 1 & 2 Kit, which was the first FDA-cleared PCR test for detecting and typing HSV-1 or HSV-2 from vaginal lesion swabs. The MultiCode technology utilizes a unique pair of synthetic nucleotide bases that allow for the highly specific and sensitive detection of multiple targets in a single reaction. EraGen's business model centered on selling these molecular reagent products and diagnostic kits to clinical laboratories, with reported product revenue of approximately $8.0 million in 2010.